asco@alo33:161487 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/asco@alo33/sourceid/161487","sourcedb":"asco@alo33","sourceid":"161487","text":" Background: The mCRPC patient population is heterogeneous, and clinical outcomes are influenced by clinical presentation and treatment history. Using the Prostate Cancer Registry NCT02236637 database, e assessed hether the subset of mCRPC patients ith metastatic M status at initial diagnosis represents patients ith different clinical and disease characteristics in a real-life context. Methods: We report findings from the first 1323 consecutive patients in the Prostate Cancer Registry, a 3-year, prospective, observational study of the routine management of 3000 patients ith mCRPC across Europe. Results: Of the 1323 patients analyzed, 549 had distant metastases at initial diagnosis M1, 41.5 percent , 526 did not M0, 39.8 percent , and 248 ere not evaluable Mx, 18.7 percent . Conclusions: In this sample of 1323 men ith mCRPC in routine practice, a higher percentage ith M1 at diagnosis presented ith aggressive and extended disease at mCRPC. M status at initial diagnosis may be a critical indicator of future treatment and prognosis in mCRPC, and follo-up of these patients over the course of the study ill clarify ho these differences and subsequent treatment may affect clinical outcomes. ltcaption class=mtgabstract-table-title Characteristics.ltth class=border-bottom align-left rospan=2 At initial diagnosisltth class=border-bottom-broken colspan=3 M stageM0M1MxPatients, n526549248Mean SD patient age, years73.6 7.2 70.6 8.6 74.2 7.7 75 years, n percent 241 45.8 187 34.1 128 51.6 Gleason score 8-10, n percent 218 44.6 331 66.5 118 52.7 Prior to study entryYears from diagnosis to CRPC, median range 6.2 0-20 2.4 0-16 5.5 0-29 Years from first M diagnosis to study entry, median range 2.0 0-15 2.5 0-13 1.9 0-11 Radical prostatectomy, n percent 204 38.8 31 5.6 69 27.8 Prostate radiotherapy, n percent 300 57.0 49 8.9 84 33.9 At study entryProstate-specific antigen, ngmL, median range 45.9 0.0-5910.0 61.7 0.0-10710.0 46.1 0.0-2530.5 Bone lesions, n percent a049 13.5 8 1.9 14 7.9 1-20208 57.5 228 55.2 110 61.8 2049 13.5 75 18.2 21 11.8 ECOG PS, n percent a0-1436 87.2 426 83.4 201 87.4 251 10.2 71 13.9 21 9.1 Any analgesic therapy, n percent 192 36.5 274 49.9 111 44.8 ltfn id=TF-161487-001-1 ltp class=mtgabstract-table-fn SD, standard deviation. a Some patients not evaluable.lttable-rap-foot ,J Clin Oncol 34, 2016 suppl; abstr 5024 00:00.0,Genitourinary Prostate Cancer \n","tracks":[{"project":"ASCO_abstracts","denotations":[{"id":"T1","span":{"begin":156,"end":171},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":470,"end":485},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":831,"end":834},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":1414,"end":1416},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":2319,"end":2321},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":2455,"end":2471},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0008315"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0008315"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"0017169"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"0011449"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"0011449"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"0008315"},{"subj":"T1","pred":"source","obj":"ASCO_abstracts"},{"subj":"T2","pred":"source","obj":"ASCO_abstracts"},{"subj":"T3","pred":"source","obj":"ASCO_abstracts"},{"subj":"T4","pred":"source","obj":"ASCO_abstracts"},{"subj":"T5","pred":"source","obj":"ASCO_abstracts"},{"subj":"T6","pred":"source","obj":"ASCO_abstracts"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"ASCO_abstracts","color":"#eca093","default":true}]}]}}